IRVINE, Calif. & CLEVELAND--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a leading global provider of medical technology and hospital automation solutions, and Cleveland Clinic, a nonprofit academic medical center, announced today the launch of a new partnership centered around hospital-based remote patient monitoring (RPM), including TeleCritical Care.

加利福尼亚州欧文市和克利夫兰市--（商业新闻短讯）--全球领先的医疗技术和医院自动化解决方案提供商Masimo（纳斯达克：MASI）和非营利学术医疗中心克利夫兰诊所今天宣布启动一项新的合作伙伴关系，该合作伙伴关系以医院远程患者监测（RPM）为中心，包括远程重症监护。

This will include the integration of Cleveland Clinic’s critical care (eHospital) and non-critical care (eCMU) central patient monitoring platforms with the Masimo Hospital Automation™ platform. The goal is to provide tools for clinicians that offer enhanced situational awareness and clinical decision-support for hospitalized patients, including the critically ill..

这将包括克利夫兰诊所的重症监护（eHospital）和非重症监护（eCMU）中央患者监测平台与Masimo Hospital Automation™平台的集成。目标是为临床医生提供工具，为住院患者（包括重症患者）提供增强的情景意识和临床决策支持。。

The collaboration will include joint development initiatives on predictive analytics and AI-based algorithms for improving cardiac care.

该合作将包括关于预测分析和基于AI的算法的联合开发计划，以改善心脏护理。

Cleveland Clinic’s existing critical care and non-critical care central monitoring platform provides continuous monitoring of a range of vital signs, including ECG, for both ICU and non-ICU patients at more than a 2,000-bed capacity. Its hospital-based RPM programs serve 11 hospitals, providing intensivist monitoring, 24/7 critical care nursing, and patient management.

克利夫兰诊所现有的重症监护和非重症监护中心监测平台为ICU和非ICU患者提供了一系列生命体征的连续监测，包括心电图，床位超过2000张。其基于医院的RPM计划服务于11家医院，提供强化监测，全天候重症监护护理和患者管理。

Cleveland Clinic’s programs1 have reduced patient mortality and reduced ICU length of stay while increasing caregiver satisfaction.2 With this partnership, Masimo and Cleveland Clinic hope to bring these innovations and patient benefits to other healthcare systems in the future. The aim of the enhanced program is to increase awareness and facilitate triage with proactive responses to changes in a patient’s condition.

克利夫兰诊所的计划1降低了患者死亡率，缩短了ICU住院时间，同时提高了护理人员的满意度。2通过这种合作关系，Masimo和克利夫兰诊所希望在未来为其他医疗保健系统带来这些创新和患者利益。增强计划的目的是提高意识，并通过对患者病情变化的积极反应来促进分诊。

This improves patient care and saves lives by ensuring the highest risk patients are identified and receive timely treatment while maintaining quality of care for all patients.1,2.

这通过确保识别出风险最高的患者并及时接受治疗，同时保持所有患者的护理质量，从而改善了患者护理并挽救了生命。1,2。

The Masimo Hospital Automation platform offers technologies designed to help clinicians improve patient care at the bedside, across the care continuum. Masimo Hospital Automation includes monitoring and wearable technologies, high-fidelity medical device integration, system-wide applications for surveillance and data visualization, and novel AI capabilities that support intelligent patient prioritization and help clinicians identify changes in patients’ condition more efficiently..

Masimo医院自动化平台提供的技术旨在帮助临床医生在整个护理过程中改善床边的患者护理。Masimo医院自动化包括监测和可穿戴技术、高保真医疗设备集成、用于监测和数据可视化的全系统应用程序，以及支持智能患者优先排序并帮助临床医生更有效地识别患者病情变化的新型人工智能功能。。

These decision-support tools are integrated into the Masimo Hospital Automation platform and utilize the Halo engine, technology which identifies deterioration patterns in multiple physiological parameters simultaneously, in real time. The Halo tools include Halo ION®, a comprehensive, scalable, and customizable continuous early warning score to help streamline patient assessment and clinical workflows.

这些决策支持工具被集成到Masimo医院自动化平台中，并利用Halo引擎，该技术可实时同时识别多个生理参数的恶化模式。Halo工具包括Halo-ION®，这是一种全面、可扩展且可定制的连续预警评分，有助于简化患者评估和临床工作流程。

As part of their work together, Masimo and Cleveland Clinic are partnering to jointly develop an additional Halo-based decision-support tool to support clinicians with earlier detection of adverse events – ultimately helping them manage and improve patient outcomes more effectively, for low-, mid-, and high-acuity patients..

作为他们共同工作的一部分，Masimo和克利夫兰诊所正在合作，共同开发一种额外的基于光晕的决策支持工具，以支持临床医生尽早发现不良事件，最终帮助他们更有效地管理和改善低、中、高视力患者的患者预后。。

“We see great opportunities to enhance remote care, particularly for critically ill individuals,” said Chiedozie Udeh, M.D., Medical Director of ICU Operations at Cleveland Clinic. “By combining our technical and clinical expertise, we aim to improve situational awareness for clinicians and continue to improve outcomes for patients.”.

克利夫兰诊所ICU操作医学主任Chiedozie Udeh医学博士说：“我们看到了加强远程护理的巨大机会，特别是对于危重病人。”。“通过结合我们的技术和临床专业知识，我们旨在提高临床医生的情景意识，并继续改善患者的预后。”。

Thomas Callahan, M.D., Staff Cardiologist at Cleveland Clinic’s Heart, Vascular & Thoracic Institute, and principal investigator for the AI study, added, “We look forward to exploring the effects of next-gen inpatient wearables, and as the capabilities of AI continue to advance, studying the potential impact on the care of cardiac patients, including those undergoing cardiac surgery.”.

克利夫兰诊所心脏，血管与胸廓研究所的心脏病专家兼人工智能研究的首席研究员托马斯·卡拉汉（ThomasCallahan）医学博士补充道：“我们期待着探索下一代住院患者可穿戴设备的影响，随着人工智能能力的不断提高，研究对心脏病患者（包括接受心脏手术的患者）护理的潜在影响。”。

Joe Kiani, Founder and CEO of Masimo, said, “We are truly honored to have the opportunity to partner with Cleveland Clinic to advance patient care. By harnessing Masimo’s AI-powered decision support tools, automation solutions, and monitoring devices, alongside Cleveland Clinic’s vast clinical expertise and dedication to providing the highest quality, most innovative care, our partnership has the potential to significantly ease staff shortages, better standardize care, and promote intensivist- and specialist-led care.

Masimo创始人兼首席执行官乔·基亚尼（JoeKiani）表示：“我们非常荣幸有机会与克利夫兰诊所（Cleveland Clinic）合作，推进患者护理。通过利用Masimo人工智能支持的决策支持工具、自动化解决方案和监测设备，以及克利夫兰诊所（Cleveland Clinic）丰富的临床专业知识和致力于提供最高质量、最具创新性的护理，我们的合作伙伴关系有可能显着缓解员工短缺，更好地标准化护理，并促进强化和专家主导的护理。

Ultimately, we will make significant strides in shifting from reactive to predictive and proactive care – improving patient outcomes, safety, and quality of care across the board.”.

最终，我们将在从反应性护理转变为预测性和主动性护理方面取得重大进展，全面改善患者预后，安全性和护理质量。”。

Dr. Chiedozie Udeh has a conflict of interest with Cleveland Clinic’s eHospital platform and may benefit from commercialization of eHospital technology developed by the Company. These financial interests are being managed by Cleveland Clinic and are within permissible limits established by the Institutional Conflicts of Interest Policy.

Chiedozie Udeh博士与克利夫兰诊所的电子医院平台存在利益冲突，可能会受益于该公司开发的电子医院技术的商业化。这些财务利益由克利夫兰诊所管理，并在机构利益冲突政策规定的允许范围内。

eHospital is not a Masimo product..

eHospital不是Masimo产品。。

@Masimo | #Masimo

@Masimo.#Masimo

About Masimo

关于Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio.

Masimo（纳斯达克股票代码：MASI）是一家全球医疗技术公司，开发和生产各种行业领先的监测技术，包括创新的测量、传感器、患者监护仪以及自动化和连接解决方案。此外，Masimo Consumer Audio拥有八个传奇音频品牌，包括Bowers&Wilkins、Denon、Marantz和Polk Audio。

Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at all 10 top U.S.

我们的使命是改善生活，改善患者预后，降低护理成本。1995年推出的Masimo SET®运动测量和低灌注™脉搏血氧仪已在100多项独立和客观的研究中显示出优于其他脉搏血氧仪技术。3 Masimo SET®还被证明可以帮助临床医生减少新生儿严重的早产儿视网膜病变，4改善新生儿的CCHD筛查，5当在手术后病房使用Masimo Patient SafetyNet™进行连续监测时，可以减少快速反应团队的激活，ICU的转移和成本。6-9 Masimo SET®估计可用于全球领先医院和其他医疗保健机构的2亿多患者，10并且是前10位的主要脉搏血氧仪美国。

hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.11 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™).

在2024年《新闻周刊》全球最佳医院名单中排名靠前的医院。11 2005年，Masimo引入了rainbow®脉搏CO血氧测定技术，可以无创连续监测以前只能有创测量的血液成分，包括总血红蛋白（SpHb®），氧含量（SpOC™），碳氧血红蛋白（SpCO®），高铁血红蛋白（SpMet®），Pleth变异指数（PVi®），RPVi™（rainbow®PVi）和氧储备指数（ORi™）。

In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilita.

2013年，Masimo推出了Root®患者监测和连接平台，该平台从头开始构建，尽可能灵活和可扩展，以方便使用。

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

RPVi尚未获得FDA 510（k）许可，也无法在美国销售。商标Patient SafetyNet的使用已获得大学健康系统联盟（University HealthSystem Consortium）的许可。

References

参考文献

Cantillon et al JAMA 15-10101. Issued August 2016.

Cantillon等人JAMA 15-10101。2016年8月发布。

Udeh C, Canfield C, Brown A et al. ICU Telemedicine and Clinical Factors Related to 30-Day Mortality: A Retrospective Cohort Study, Critical Care Medicine. January 2021 - Volume 49 - Issue 1 - p 9 doi: 10.1097/01.ccm.0000726092.34718.60.

Udeh C，Canfield C，Brown A等。ICU远程医疗和与30天死亡率相关的临床因素：回顾性队列研究，重症监护医学。2021年1月-第49卷-第1期-第9页doi:10.1097/01.ccm.0000726092.34718.60。

Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.

已发表的脉搏血氧仪临床研究和Masimo SET®的益处可在我们的网站上找到http://www.masimo.com.比较研究包括独立和客观的研究，这些研究由科学会议上发表的摘要和同行评审的期刊文章组成。

Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

Castillo A等人。通过改变临床实践和SpO2技术预防早产儿视网膜病变。。2011年2月；100（2）：188-92。

de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.

de Wahl-Granelli A等人。脉搏血氧仪筛查对导管依赖性先天性心脏病检测的影响：一项针对39821名新生儿的瑞典前瞻性筛查研究。英国医学杂志。2009年；1月8日；338

Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.

Taenzer A等人。脉搏血氧仪监测对救援事件和重症监护病房转移的影响：前后并发研究。麻醉学。。

Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

Taenzer A等人。术后监测-达特茅斯经验。麻醉患者安全基金会新闻稿。2012年春夏。

McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

McGrath S等人。普通护理病房的监测管理：策略，设计和实施。质量和患者安全联合委员会杂志。2016年7月；42（7）：293-302。

McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.

McGrath S等人。与镇静和镇痛药物相关的住院呼吸骤停：持续监测对患者死亡率和严重发病率的影响。J患者Saf。2020年3月14日DOI:10.1097/PTS.0000000000000696。

Estimate: Masimo data on file.

估计：Masimo数据存档。

https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

Forward-Looking Statements

前瞻性声明

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Hospital Automation™, Halo, and Halo ION®.

本新闻稿包括1933年《证券法》第27A节和1934年《证券交易法》第21E节中定义的与1995年《私人证券诉讼改革法》相关的前瞻性声明。这些前瞻性声明包括关于Masimo Hospital Automation™、Halo和Halo ION®潜在有效性的声明。

These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Hospital Automation, Halo, and Halo ION, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks that Masimo may not realize the expected benefits and goals that may be achieved by its collaboration with Cleveland Clinic; risks that Masimo and Cleveland Clinic fail to collaborate in the areas stated in this press release as planned; risks related to COVID-19; as well as other factors discussed in the 'Risk Factors' section of our most recent reports filed with the Securities and Exchange Commission ('SEC'), which may be obtained for free at the SEC's website at www.sec.gov.

；与我们相信Masimo独特的无创测量技术（包括医院自动化，光环和光环离子）有助于积极的临床结果和患者安全相关的风险；与我们相信Masimo非侵入性医疗突破提供成本效益高的解决方案和独特优势有关的风险；Masimo可能无法实现与克利夫兰诊所合作可能实现的预期收益和目标的风险；Masimo和克利夫兰诊所未能按计划在本新闻稿所述领域合作的风险；与新型冠状病毒相关的风险；以及我们向美国证券交易委员会（“SEC”）提交的最新报告中“风险因素”部分讨论的其他因素，这些报告可以在SEC的网站www.SEC.gov上免费获得。

Although we believe that the expectations reflected in our forward-looking statements.

虽然我们相信这些期望反映在我们的前瞻性声明中。